Affinage

SEMA3F

Semaphorin-3F · UniProt Q13275

Length
785 aa
Mass
88.4 kDa
Annotated
2026-04-28
39 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SEMA3F is a secreted class 3 semaphorin that functions as a repulsive guidance cue and tumor suppressor by signaling through heteromeric receptor complexes containing neuropilin-2 (NRP2) and plexins (PlexinA1, PlexinA3) to reorganize the actin cytoskeleton, inhibit cell adhesion and migration, and regulate synaptic plasticity. Receptor engagement activates ABL2/ARG kinase, which phosphorylates p190RhoGAP to inactivate RhoA, causing cytoskeletal collapse, while simultaneously suppressing ILK–ERK1/2, PI3K–AKT–STAT3, and HIF-1α signaling to reduce integrin activation, VEGF expression, and tumor angiogenesis (PMID:18660502, PMID:17875711, PMID:25866254). In the nervous system, SEMA3F–NRP2 signaling repels GABAergic interneurons during cortical migration, establishes olfactory bulb topography, mediates axon pruning through CRMP2, and drives homeostatic downscaling of synaptic AMPA receptors via NRP2/PlexinA3 (PMID:12454988, PMID:20550939, PMID:31919978, PMID:29154130). SEMA3F requires furin-mediated proteolytic processing for activity, and loss-of-function variants in SEMA3F cause hearing loss with aberrant spiral ganglion neuron projections and are associated with idiopathic hypogonadotropic hypogonadism (PMID:39909336, PMID:33495532).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2003 High

    Establishing that SEMA3F is a functional anti-adhesive/chemorepulsive ligand acting through neuropilins answered whether secreted semaphorins directly regulate tumor cell behavior and identified NRP2 as the preferred receptor.

    Evidence Cell adhesion/spreading assays with anti-NRP1/NRP2 blocking antibodies in breast cancer cells; GABAergic neuron repulsion assays on neocortical slices with in vivo ectopic expression

    PMID:12454988 PMID:12659673

    Open questions at the time
    • Downstream intracellular signaling cascade not yet identified
    • Plexin co-receptor requirement not addressed
    • In vivo tumor-suppressive function not tested
  2. 2005 High

    In vivo epistasis experiments established that NRP2, not NRP1, is the required receptor for SEMA3F's antitumor activity and linked downstream effects to integrin inactivation and MAPK suppression.

    Evidence Orthotopic lung cancer models comparing NRP1-only vs NRP2-expressing cells; chemorepulsion vs adhesion-disruption phenotypes in matched breast cancer lines

    PMID:15802023 PMID:15967098

    Open questions at the time
    • Direct plexin requirement not dissected
    • How NRP2 engagement leads to integrin inactivation was unknown
  3. 2005 Medium

    Demonstrating that SEMA3F is epigenetically silenced in lung cancer through promoter-associated histone modifications revealed a non-genetic mechanism for its loss in tumors.

    Evidence Methylation-specific PCR and TSA/5-aza treatment in lung cancer cell lines

    PMID:16005989

    Open questions at the time
    • Specific histone modifier responsible not identified
    • Causal link between methylation mark and in vivo tumor progression not established
  4. 2007 High

    Identification of the ILK–ERK1/2, AKT–STAT3, and HIF-1α axes as SEMA3F-suppressed pathways explained how SEMA3F reduces VEGF and tumor angiogenesis in vivo.

    Evidence ILK kinase assay, ILK siRNA epistasis, phospho-protein immunoblotting, HIF-1α degradation assays, nude mouse xenograft with microvessel density quantification

    PMID:17875711

    Open questions at the time
    • Molecular link between NRP2 engagement and ILK inhibition not defined
    • Relative contribution of each pathway to in vivo tumor suppression unclear
  5. 2008 High

    Discovery that ABL2/ARG kinase binds PlexinA1 cytoplasm and phosphorylates p190RhoGAP to inactivate RhoA provided the first complete intracellular signaling cascade from SEMA3F receptor to cytoskeletal collapse.

    Evidence Co-immunoprecipitation, in vitro kinase assay, dominant-negative ABL2, RhoA activity assay in glioma and endothelial cells

    PMID:18660502

    Open questions at the time
    • Whether this pathway operates in all SEMA3F-responsive cell types was not tested
    • Relationship between RhoA inactivation and the integrin/ILK pathway not resolved
  6. 2010 High

    Demonstration that Sema3F deposited by early-arriving axons repels Nrp2-positive later-arriving axons established a temporal mechanism for olfactory bulb topographic map formation.

    Evidence Nrp2 and Sema3F knockout mice with axon tracing and olfactory map analysis

    PMID:20550939

    Open questions at the time
    • Whether the same mechanism applies to other sensory maps not addressed
    • Intracellular signaling downstream of Nrp2 in OSN axons not dissected
  7. 2012 High

    Identification of RORα as a direct transcriptional activator of SEMA3F connected a nuclear receptor to semaphorin-mediated tumor suppression.

    Evidence ChIP showing RORα at SEMA3F promoter, luciferase reporter assay, siRNA epistasis in 3D culture and nude mouse models

    PMID:22350413

    Open questions at the time
    • Whether RORα regulation is tissue-specific not established
    • Other transcription factors regulating SEMA3F not characterized
  8. 2015 High

    Receptor reconstitution in lymphatic endothelial cells confirmed NRP2 as the essential coreceptor for SEMA3F and demonstrated anti-lymphangiogenic and anti-metastatic activity in head and neck cancer.

    Evidence Plexin/neuropilin combination reconstitution in LECs, LEC collapse assay, orthotopic HNSCC metastasis mouse model

    PMID:25952650

    Open questions at the time
    • Specific plexin partner required in LECs not fully resolved
    • Whether anti-lymphangiogenic effect is independent of anti-angiogenic effect unclear
  9. 2015 High

    Demonstrating that SEMA3F suppresses colorectal cancer metastasis through PI3K–AKT-dependent downregulation of the ASCL2–CXCR4 axis revealed a chemokine-receptor pathway as a distal effector.

    Evidence SEMA3F knockdown/overexpression with CXCR4 antagonist AMD3100 rescue in vitro and in xenograft metastasis model

    PMID:25866254

    Open questions at the time
    • Whether ASCL2–CXCR4 axis suppression is generalizable beyond colorectal cancer not tested
    • Direct link from NRP2 to PI3K inhibition not mechanistically detailed
  10. 2017 High

    Discovery that Sema3F mediates homeostatic synaptic downscaling by regulating surface AMPA receptors through NRP2/PlexinA3 extended its function beyond guidance into activity-dependent synaptic plasticity.

    Evidence Co-immunoprecipitation of NRP2 with GluA1, genetic KO of Npn-2 and PlexA3, surface AMPAR quantification, electrophysiology

    PMID:29154130

    Open questions at the time
    • Signaling cascade between PlexA3 and AMPAR internalization not defined
    • Source of activity-dependent Sema3F release not identified
  11. 2017 High

    Finding that Sema3F promotes extraembryonic angiogenesis by stabilizing Myc and suppressing Thbs1 revealed a pro-angiogenic role in development, contrasting with its anti-angiogenic tumor function.

    Evidence Sema3f-null mouse, AAV overexpression, F9 cell differentiation, Myc phosphorylation/degradation assays

    PMID:28729362

    Open questions at the time
    • Receptor complex mediating this effect in yolk sac not identified
    • How Sema3F inhibits Myc phosphorylation mechanistically not resolved
  12. 2020 High

    Identification of CRMP2 as a downstream effector of Sema3F in axon pruning and dendritic spine remodeling, with behavioral consequences resembling ASD, connected guidance signaling to neurodevelopmental disorders.

    Evidence crmp2-/- mice with axon pruning and spine morphometry analysis, in vitro Sema3F signaling in primary neurons, behavioral testing

    PMID:31919978

    Open questions at the time
    • Direct phosphorylation of CRMP2 by Sema3F pathway components not demonstrated
    • Whether SEMA3F variants contribute to ASD in humans not established
  13. 2020 Medium

    Demonstrating that EZH2-mediated H3K27me3 at the SEMA3F promoter, stabilized by lncRNA FAM83C-AS1/ZRANB1, silences SEMA3F identified the specific epigenetic repressor complex responsible for its loss in colorectal cancer.

    Evidence H3K27me3 ChIP at SEMA3F promoter, EZH2 stabilization assay, ZRANB1 co-IP, epistatic rescue in vitro and in vivo

    PMID:33109776

    Open questions at the time
    • Whether this EZH2 mechanism operates across cancer types not tested
    • Single-lab finding not independently confirmed
  14. 2025 High

    Establishing that furin-mediated proteolytic processing is essential for SEMA3F activity, and that inner ear-specific Sema3f loss causes hearing impairment with aberrant spiral ganglion neuron projections, defined a new sensory phenotype and a required activation step.

    Evidence In vitro furin cleavage assay with patient-derived variants, F-actin collapse assay in HUVECs, inner ear-specific Sema3f KO mice with ABR testing

    PMID:39909336

    Open questions at the time
    • Furin cleavage site(s) not mapped at residue resolution
    • Whether hearing loss is purely neuronal guidance-based or involves vascular dysfunction not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular link between NRP2 engagement and suppression of ILK activity, the receptor complex mediating Sema3F's pro-angiogenic function in yolk sac, the mechanism by which SEMA3F stabilizes Myc, and structural details of the active processed SEMA3F–NRP2–PlexinA complex remain undefined.
  • No structural model of processed SEMA3F bound to its holoreceptor
  • Mechanism linking receptor to ILK inhibition unknown
  • How context determines pro- vs anti-angiogenic outcome not resolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 5 GO:0098772 molecular function regulator activity 3
Localization
GO:0005576 extracellular region 5
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 4 R-HSA-112316 Neuronal System 2
Partners
ABL2CRMP2GJA1NRP1NRP2PLXNA1PLXNA3

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 SEMA3F forms a complex with NRP2 (neuropilin-2) and plexin A1, triggering a signaling cascade in which ABL2/ARG tyrosine kinase directly binds the cytoplasmic domain of plexin A1, phosphorylates and activates p190RhoGAP, which inactivates RhoA (GTP→GDP), resulting in cytoskeletal collapse and inhibition of cell migration in glioma and endothelial cells. Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown of ABL2 and p190RhoGAP, dominant-negative ABL2 mutant overexpression, RhoA activity assay The Journal of biological chemistry High 18660502
2003 SEMA3F inhibits cell attachment, spreading, lamellipodia extension, and membrane ruffling in breast cancer cells; these effects are mediated through NRP1 in MCF7 cells and NRP2 in C100 cells, and are antagonized by VEGF, which has opposite pro-adhesive effects. SEMA3F binds NRP2 with ~10-fold greater affinity than NRP1. Cell adhesion/spreading assays, blocking anti-NRP1/NRP2 antibodies, time-lapse microscopy of Rac1-GFP, receptor expression profiling Neoplasia (New York, N.Y.) High 12659673
2005 SEMA3F exerts a chemorepulsive effect on motile breast cancer cells via NRP2, while in less motile MCF7 cells (NRP1-only) it inhibits E-cadherin- and β-catenin-mediated cell contacts at the membrane, reducing spreading and proliferation without inducing motility. 3D culture migration assay, neurobiological stripe assay adapted for tumor cells, anti-NRP1/NRP2 blocking antibodies, immunofluorescence for E-cadherin and β-catenin Neoplasia (New York, N.Y.) High 15802023
2007 SEMA3F expression decreases integrin-linked kinase (ILK) kinase activity, activated αVβ3 integrin levels, adhesion to vitronectin, and downstream phospho-ERK1/2, phospho-AKT, and phospho-STAT3 signaling; it also reduces HIF-1α protein (via inhibition of AKT-driven translation initiation) and VEGF mRNA levels, and suppresses tumor microvessel density in vivo. Stable retroviral transfection, inducible expression systems, ILK kinase assay, ILK siRNA, phospho-protein immunoblotting, HIF-1α mRNA/protein degradation assays, nude mouse xenograft with microvessel density quantification Cancer research High 17875711
2005 SEMA3F antitumor activity in vivo (NCI-H157 lung cancer orthotopic model) requires NRP2 expression; H460 cells expressing NRP1 but not NRP2 showed no survival benefit, establishing NRP2 as the functional receptor for SEMA3F's antitumor signaling in this context. The effect was associated with loss of activated αVβ3 integrin and reduced MAPK phosphorylation. Stable retroviral transfection, orthotopic nude rat tumor model, receptor expression profiling, integrin activation assay, phospho-ERK immunoblotting Neoplasia (New York, N.Y.) High 15967098
2010 In the mouse olfactory system, Sema3F is secreted by early-arriving OSN axons and deposited at the anterodorsal olfactory bulb, where it repels later-arriving Nrp2-positive axons, establishing dorsal-ventral topographic map formation through sequential axon arrival and graded complementary expression of Nrp2 and Sema3F. Nrp2 and Sema3F knockout mice, in situ hybridization, axon tracing, in vivo olfactory map analysis Cell High 20550939
2017 Sema3F signals through the Neuropilin-2/PlexinA3 holoreceptor to mediate homeostatic downscaling of synaptic AMPA receptors (GluA1) in cortical neurons in response to increased neuronal activity; Npn-2 physically associates with AMPA receptors and Sema3F regulates this interaction. Co-immunoprecipitation of Npn-2 with GluA1, genetic knockout of Npn-2 and PlexA3, surface AMPAR quantification, electrophysiology, homeostatic scaling assays Neuron High 29154130
2020 CRMP2 mediates Sema3F signaling in primary neurons to regulate axon pruning in hippocampus and visual cortex and dendritic spine remodeling; crmp2-/- mice display prominent defects consistent with impaired Sema3F signaling, including ASD-related social behavior changes. crmp2-/- knockout mice, in vitro Sema3F signaling assays in primary neurons, stereotyped axon pruning analysis, dendritic spine morphometry, behavioral testing EMBO reports High 31919978
2015 SEMA3F acts predominantly through NRP2 to induce lymphatic endothelial cell (LEC) collapse and inhibit lymphangiogenesis; reconstitution of all plexin/neuropilin combinations in LECs showed NRP2 is the primary required coreceptor for SEMA3F signaling in LECs, and re-expression of SEMA3F in orthotopic HNSCC mouse models diminished lymphangiogenesis and lymph node metastasis. Recombinant SEMA3F protein, LEC collapse assay, reconstitution of plexin/neuropilin combinations, in vivo lymphangiogenesis assay, orthotopic HNSCC metastasis mouse model Cancer research High 25952650
2015 SEMA3F inhibits invasion and metastasis of colorectal cancer cells through PI3K-AKT-dependent downregulation of the ASCL2-CXCR4 axis; CXCR4 antagonist AMD3100 rescued the metastasis-suppressive effect of SEMA3F knockdown both in vitro and in vivo. SEMA3F knockdown/overexpression, invasion assays, xenograft metastasis model, CXCR4 antagonist (AMD3100) rescue, PI3K-AKT pathway inhibition The Journal of pathology High 25866254
2012 RORα directly regulates SEMA3F transcription; chromatin immunoprecipitation and luciferase reporter assays showed RORα binds the SEMA3F promoter, and SEMA3F knockdown in RORα-expressing cancer cells rescued aggressive 3D phenotypes and tumor invasion, placing SEMA3F downstream of RORα as a mediator of tumor suppression. Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA knockdown, 3D culture morphogenesis assay, nude mouse tumor model Cancer research High 22350413
2007 SEMA3F directly binds to the cytoplasmic loop domain of connexin 43 (Cx43), controlling Cx43 localization at the plasma membrane and gap junctional intercellular communication (GJIC); siRNA knockdown of SEMA3F in IAR20 cells reduced membrane-associated Cx43 and GJIC activity. Yeast two-hybrid complementation and screening, immunofluorescence co-localization, siRNA knockdown of SEMA3F, GJIC functional assay The Journal of membrane biology Medium 17665084
2003 Sema3F expressed by COS1 cell clusters placed on neocortical slices repels Nrp2-positive GABAergic neurons migrating from the ganglionic eminence; in vivo ectopic Sema3F expression diverts Dlx2-positive cells to the upper intermediate zone, demonstrating a role for Sema3F-Nrp2 interaction in sorting GABAergic interneurons during neocortical development. COS1 cell cluster placement on embryonic neocortical slices, in vivo ectopic expression, in situ hybridization for receptor expression, anti-NRP2 blocking The Journal of comparative neurology High 12454988
2005 SEMA3F promoter is regulated epigenetically; methylation of a specific region (position −3850 to −3644) correlates with loss of expression in lung cancer cell lines, and histone deacetylase inhibition with Trichostatin A is more effective than demethylation (5-aza-2'-deoxycytidine) in restoring SEMA3F expression, indicating chromatin remodeling is the primary epigenetic mechanism of repression. Southern blot, methylation-specific PCR, transcriptional initiation site mapping, Trichostatin A and 5-aza-2'-deoxycytidine treatment, RT-PCR expression analysis Biochimica et biophysica acta Medium 16005989
2017 In visceral yolk sac epithelial cells, Sema3F signals to inhibit phosphorylation-dependent degradation of Myc, stabilizing Myc and driving expression of the pro-angiogenic miR-17/92 cluster while suppressing Thbs1 (thrombospondin 1), thereby promoting extraembryonic (but not intraembryonic) angiogenesis. Sema3f-null mouse characterization, AAV-mediated in vivo overexpression, F9 cell differentiation in vitro, exogenous recombinant Sema3F treatment, Myc phosphorylation/degradation assays, miRNA expression profiling, Thbs1 and Vegf pathway analysis Arteriosclerosis, thrombosis, and vascular biology High 28729362
2021 SEMA3F signaling through PLXNA1-A3 receptors guides GnRH neurons and olfactory/vomeronasal nerve fibers; loss-of-function variants in SEMA3F and PLXNA3 identified in IHH patients were functionally validated in HEK293T cells as deleterious, and SEMA3F/PLXNA3 were shown to be expressed along the olfactory nerve and GnRH neuron migratory pathway in early human fetal development. Exome sequencing of IHH patients, transient transfection functional assays in HEK293T, fluorescent immunohistochemistry on human fetal tissue Genetics in medicine Medium 33495532
2017 Sema3f protects against subretinal neovascularization in vivo; AAV-mediated overexpression of Sema3f reduced pathological neovascularization by 56% in the Vldlr-/- model and intravitreal Sema3f injection reduced choroidal neovascularization by 30% in the laser-induced CNV model. AAV overexpression in Vldlr-/- mice, intravitreal recombinant protein injection in laser-induced CNV mouse model, neovascularization quantification EBioMedicine Medium 28373097
2025 Furin-mediated proteolytic processing is required for SEMA3F function; missense variants identified in a hearing-loss patient reduced furin-mediated processing of SEMA3F and abolished its ability to collapse the filamentous actin cytoskeleton in HUVECs. Inner ear-specific Sema3f knockout mice showed hearing loss with abnormal spiral ganglion neuron projections. In vitro furin cleavage assay with variant SEMA3F proteins, F-actin collapse assay in HUVECs, inner ear-specific Sema3f knockout mice, auditory brainstem response and DPOAE testing, spiral ganglion neuron projection analysis Molecules and cells High 39909336
2012 Sema3F downregulates p53 expression in primary hippocampal neurons, contributing to axonal growth cone collapse; overexpression of p53 partially reversed Sema3F-induced growth cone collapse, and p53 inhibition/siRNA knockdown alone induced collapse, establishing p53 as a downstream mediator of Sema3F's collapsing activity. Primary hippocampal neuron culture, Sema3F treatment, p53 siRNA knockdown, p53 inhibitor, p53 overexpression, growth cone morphometry International journal of clinical and experimental pathology Low 22977659
2020 lncRNA FAM83C-AS1 epigenetically silences SEMA3F by stabilizing EZH2 protein through recruitment of ZRANB1, leading to increased H3K27me3 methylation at the SEMA3F promoter; SEMA3F is required for the tumor-suppressive effects of FAM83C-AS1 knockdown in colorectal cancer. EZH2 stabilization assay, H3K27me3 ChIP at SEMA3F promoter, ZRANB1 co-IP, FAM83C-AS1 knockdown with SEMA3F rescue in vitro and in vivo Aging Medium 33109776
2025 A bispecific antibody that dimerizes PLXNA1 and NRP2 (the SEMA3F receptor complex) mimics NRP2-mediated SEMA3F signaling, suppressing phospho-AKT, oncogene expression, and cell proliferation; structural studies showed the bsAb binds PLXNA1/NRP2 at sites distinct from the SEMA3F-binding site but allows proper receptor complex formation for signaling. Bispecific antibody engineering, receptor dimerization assay, phospho-AKT assay, cell proliferation assay, structural analysis of antibody-receptor binding The Journal of biological chemistry Medium 41391772

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 131 8786119
2003 Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. The Journal of pathology 122 12845630
2010 Sequential arrival and graded secretion of Sema3F by olfactory neuron axons specify map topography at the bulb. Cell 111 20550939
2012 RORα suppresses breast tumor invasion by inducing SEMA3F expression. Cancer research 99 22350413
2000 Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. The American journal of pathology 96 10702410
2008 ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. The Journal of biological chemistry 93 18660502
2003 Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia (New York, N.Y.) 93 12659673
2005 Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia (New York, N.Y.) 91 15802023
2003 Evidence that Sema3A and Sema3F regulate the migration of GABAergic neurons in the developing neocortex. The Journal of comparative neurology 90 12454988
2007 Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer research 71 17875711
2017 Neuropilin-2/PlexinA3 Receptors Associate with GluA1 and Mediate Sema3F-Dependent Homeostatic Scaling in Cortical Neurons. Neuron 61 29154130
2005 Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (New York, N.Y.) 60 15967098
2007 Effects of different regions of the developing gut on the migration of enteric neural crest-derived cells: a role for Sema3A, but not Sema3F. Developmental biology 51 17362911
2020 CRMP2 mediates Sema3F-dependent axon pruning and dendritic spine remodeling. EMBO reports 41 31919978
2015 Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma. Cancer research 40 25952650
2015 SEMA3F prevents metastasis of colorectal cancer by PI3K-AKT-dependent down-regulation of the ASCL2-CXCR4 axis. The Journal of pathology 38 25866254
2022 The dual role of boron in vitro neurotoxication of glioblastoma cells via SEMA3F/NRP2 and ferroptosis signaling pathways. Environmental toxicology 25 36136913
2005 Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochimica et biophysica acta 25 16005989
2021 Loss-of-function variants in SEMA3F and PLXNA3 encoding semaphorin-3F and its receptor plexin-A3 respectively cause idiopathic hypogonadotropic hypogonadism. Genetics in medicine : official journal of the American College of Medical Genetics 24 33495532
2017 Sema3f Protects Against Subretinal Neovascularization In Vivo. EBioMedicine 22 28373097
2017 The crucial role of SEMA3F in suppressing the progression of oral squamous cell carcinoma. Cellular & molecular biology letters 17 29299034
2007 Control of intracellular localization and function of Cx43 by SEMA3F. The Journal of membrane biology 17 17665084
2020 The oncogenic role of LncRNA FAM83C-AS1 in colorectal cancer development by epigenetically inhibits SEMA3F via stabilizing EZH2. Aging 16 33109776
2020 SEMA3F Promotes Liver Hepatocellular Carcinoma Metastasis by Activating Focal Adhesion Pathway. DNA and cell biology 15 31968181
2006 Sema3D, Sema3F, and Sema5A are expressed in overlapping and distinct patterns in chick embryonic heart. Developmental dynamics : an official publication of the American Association of Anatomists 15 16261621
2017 Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arteriosclerosis, thrombosis, and vascular biology 14 28729362
2011 Expression patterns of Sema3F, PlexinA4, -A3, Neuropilin1 and -2 in the postnatal mouse molar suggest roles in tooth innervation and organogenesis. Acta odontologica Scandinavica 12 21815834
2025 Biallelic variants of SEMA3F are associated with nonsyndromic hearing loss. Molecules and cells 6 39909336
2012 Sema3F downregulates p53 expression leading to axonal growth cone collapse in primary hippocampal neurons. International journal of clinical and experimental pathology 5 22977659
2019 Changes in Expression Pattern of SEMA3F Depending on Endometrial Cancer Grade - Pilot Study. Current pharmaceutical biotechnology 4 31215376
2024 A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer. Breast cancer (Tokyo, Japan) 3 39352623
2020 Differences in the Expression Pattern of mRNA Protein SEMA3F in Endometrial Cancer in vitro under Cisplatin Treatment. Current pharmaceutical biotechnology 2 32297576
2024 The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma. Breast cancer research : BCR 1 39138514
2024 Semaphorin 3F (SEMA3F) influences patient survival in esophageal adenocarcinoma. Scientific reports 1 39232098
2023 Advances in SEMA3F regulation of clinically high-incidence cancers. Cancer biomarkers : section A of Disease markers 1 37599522
2003 [Mutation and expression of SEMA3B and SEMA3F gene in nasopharyngeal carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer 1 12561429
2025 Effect of SEMA3F on Proliferation, Migration, and Ferroptosis of Endometrial Stromal Cells in Patients with Endometriosis. Gynecologic and obstetric investigation 0 40319865
2025 Effect of Sema3F on VEGF in Primary Rat Hippocampal Neurons In vitro. Current molecular medicine 0 41029010
2025 A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F. The Journal of biological chemistry 0 41391772